CN114127060A - 二聚或多聚体形式的突变型idh抑制剂 - Google Patents

二聚或多聚体形式的突变型idh抑制剂 Download PDF

Info

Publication number
CN114127060A
CN114127060A CN202080029908.9A CN202080029908A CN114127060A CN 114127060 A CN114127060 A CN 114127060A CN 202080029908 A CN202080029908 A CN 202080029908A CN 114127060 A CN114127060 A CN 114127060A
Authority
CN
China
Prior art keywords
group
substituted
unsubstituted
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080029908.9A
Other languages
English (en)
Other versions
CN114127060B (zh
Inventor
曾蜜
吴海平
朱卫星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitas Biosciences Shanghai Co Ltd
Original Assignee
Epitas Biosciences Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitas Biosciences Shanghai Co Ltd filed Critical Epitas Biosciences Shanghai Co Ltd
Publication of CN114127060A publication Critical patent/CN114127060A/zh
Application granted granted Critical
Publication of CN114127060B publication Critical patent/CN114127060B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明提供了一种二聚或多聚体形式的突变型IDH抑制剂。具体地，本发明提供了一种式I化合物、或其药学上可接受的盐，Da‑Wa‑L‑Wb‑Db(I)。本发明的化合物具有优异的突变型IDH1抑制活性。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080029908.9A 2019-04-23 2020-04-09 二聚或多聚体形式的突变型idh抑制剂 Active CN114127060B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103301357 2019-04-23
CN201910330135.7A CN111825666B (zh) 2019-04-23 2019-04-23 二聚或多聚体形式的突变型idh抑制剂
PCT/CN2020/084041 WO2020216071A1 (zh) 2019-04-23 2020-04-09 二聚或多聚体形式的突变型idh抑制剂

Publications (2)

Publication Number Publication Date
CN114127060A true CN114127060A (zh) 2022-03-01
CN114127060B CN114127060B (zh) 2023-06-13

Family

ID=72912529

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910330135.7A Active CN111825666B (zh) 2019-04-23 2019-04-23 二聚或多聚体形式的突变型idh抑制剂
CN202080029908.9A Active CN114127060B (zh) 2019-04-23 2020-04-09 二聚或多聚体形式的突变型idh抑制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910330135.7A Active CN111825666B (zh) 2019-04-23 2019-04-23 二聚或多聚体形式的突变型idh抑制剂

Country Status (5)

Country Link
US (1) US20220267309A1 (zh)
EP (1) EP3964508A4 (zh)
JP (1) JP2022531104A (zh)
CN (2) CN111825666B (zh)
WO (1) WO2020216071A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958506A (zh) * 2011-09-27 2014-07-30 诺华股份有限公司 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
ES2651132T3 (es) * 2013-03-14 2018-01-24 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN107216312B (zh) * 2016-03-22 2023-08-01 上海海和药物研究开发股份有限公司 一种具有突变型idh抑制活性的化合物、其制备方法及用途
KR20190092476A (ko) * 2016-12-19 2019-08-07 이소큐어 바이오사이언스 인코퍼레이티드 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958506A (zh) * 2011-09-27 2014-07-30 诺华股份有限公司 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
胡玉泉: "一叶萩碱化学反应性研究及其二聚体、氨基酸轭合物的合成", 《暨南大学硕士学位论文》 *
赵桂森 等: "《新药设计与开发基础》", 30 November 2015, 山东大学出版社 *
黄禾等: "异柠檬酸脱氢酶及其突变体抑制剂在急性髓系白血病治疗领域的研究进展", 《药学进展》 *

Also Published As

Publication number Publication date
WO2020216071A1 (zh) 2020-10-29
CN114127060B (zh) 2023-06-13
EP3964508A4 (en) 2022-12-21
EP3964508A1 (en) 2022-03-09
JP2022531104A (ja) 2022-07-06
US20220267309A1 (en) 2022-08-25
CN111825666A (zh) 2020-10-27
CN111825666B (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
CN114127053B (zh) 一种取代吡嗪化合物、其制备方法和用途
US9688654B2 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
US20230219946A1 (en) Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
WO2014134774A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN113330009B (zh) 氮杂环化合物、其制备方法及用途
US20220348564A1 (en) Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same
US20210403460A1 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
AU2024201165A1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
WO2018001332A1 (zh) 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
CN110804059B (zh) 氨基甲酸酯类化合物、药物组合物及其应用
CN114127060B (zh) 二聚或多聚体形式的突变型idh抑制剂
EP3426638B1 (en) Inhibitors of indoleamine 2,3-dioxygenase
CN112574255B (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
CN111377925B (zh) 嘌呤类衍生物、其制备方法及其在医药上的应用
CN113880804A (zh) 新型苯并咪唑化合物
CN112876419A (zh) 烯丙胺衍生物及其制备方法和用途
CN111278827A (zh) 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法
CN115043844B (zh) Trk激酶抑制剂化合物及其用途
CN111662242B (zh) 杂环类idh突变体抑制剂、其制备方法及用途
US20220332714A1 (en) P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof
CN117800894A (zh) 饱和环类衍生物、包含其的药物组合物及其医药用途
CN117126140A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
KR20240021239A (ko) Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
CN115380024A (zh) 二氮杂螺吡喃化合物的晶型
CN115768775A (zh) Idh突变体抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant